Physician profile
Kevin S Barton
NPI 1609922053
$23,761.02
in general payments reported to CMS, 2019-2025
9 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Chiropractor providers received nationally (typical 2025 total: $40.91).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.15 · 2020: $44.23 · 2021: $30.02 · 2022: $143 · 2023: $149 · 2024: $186 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $23K · Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $22,997.03 |
| Food and Beverage | $486.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $22,997.03 | 2025 | |
| Nalu Medical, INC. | $222.16 | 2022-2023 | Nalu Neurostimulation System |
| Bioventus LLC | $138.38 | 2020-2025 | Xcell, Gelsyn-3, Supartz Fx Sodium Hyaluronate |
| Depuy Synthes Sales INC. | $112.08 | 2019-2025 | Monovisc, Orthovisc |
| Biotissue Holdings INC. | $111.37 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $68.60 | 2022-2025 | Zilretta, Iovera |
| Pacira Therapeutics, INC. | $67.16 | 2019-2021 | |
| Lifeward, INC. | $24.35 | 2024 | |
| Sanofi-Aventis U.S. LLC | $19.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.